Publications by authors named "Julie Strizki"

Claim this Profile
I
Impact of baseline humoral immunity on treatment outcomes with molnupiravir in the MOVe-OUT randomized, controlled trial.
Matthew G Johnson, Julie M Strizki, David W Hilbert, Ying Zhang, Patricia Carmelitano

Virology· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to "Impact of baseline humoral immunity on treatment outcomes with molnupiravir in the MOVe-OUT randomized, controlled trial" [Virology 613 (2026) 110710].
Matthew G Johnson, Julie M Strizki, David W Hilbert, Ying Zhang, Patricia Carmelitano

Virology· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: Example of the MOVe-OUT study.
Yoseph Caraco, Matthew G Johnson, Joseph A Chiarappa, Brian M Maas, Julie A Stone, Julie M Strizki

Clin Trials· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Molnupiravir Exposure-Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID-19.
Akshita Chawla, Ruthie Birger, Brian M Maas, Youfang Cao, Hong Wan, Julie Strizki

Clin Transl Sci· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytomegalovirus Antiviral Resistance Among Kidney Transplant Recipients in a Phase 3 Trial of Letermovir vs Valganciclovir Prophylaxis.
Julie M Strizki, Tracy L Diamond, Valerie L Teal, Christopher L Gilbert, Weiwen Wang

J Infect Dis· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Virologic Outcomes with Molnupiravir in Nonhospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial.
Julie M Strizki, Jay A Grobler, Nicholas Murgolo, Arthur Fridman, Matthew G Johnson

Infect Dis Ther· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT).
Matthew G Johnson, Julie M Strizki, Erin Jensen, Jonathan Cohen, Christine Katlama

Microbiol Spectr· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molnupiravir: Mechanism of action, clinical, and translational science.
Brian M Maas, Julie Strizki, Randy R Miller, Sushma Kumar, Michelle Brown

Clin Transl Sci· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance.
Julie M Strizki, John M Gaspar, John A Howe, Beth Hutchins, Hiroshi Mohri

Antimicrob Agents Chemother· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial.
Julie M Strizki, Jay A Grobler, Nicholas Murgolo, Arthur Fridman, Matthew G Johnson

Infect Dis Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial.
Sady A Alpizar, Jose Accini, Duane C Anderson, Basem Eysa, Isaí Medina-Piñón, Julie Strizki

J Infect· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial.
Matthew G Johnson, Julie M Strizki, Michelle L Brown, Hong Wan, Hala H Shamsuddin

Infection· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
Ajit P Limaye, Klemens Budde, Atul Humar, Flavio Vincenti, Dirk R J Kuypers, Julie M Strizki

JAMA· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Evaluation of Nanoparticles-in-Film Technology to Achieve Extended In Vivo Exposure of MK-2048 for HIV Prevention.
Xin Tong, Sravan Kumar Patel, Jing Li, Dorothy Patton, Elaine Xu, Julie Strizki

Polymers (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
Angélica Jayk Bernal, Monica M Gomes da Silva, Dany B Musungaie, Evgeniy Kovalchuk, Antonio Gonzalez, Julie Strizki

N Engl J Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19.
José R Arribas, Sanjay Bhagani, Suzana M Lobo, Ilsiyar Khaertynova, Lourdes Mateu, Julie Strizki

NEJM Evid· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults.
Yoseph Caraco, Gordon E Crofoot, Pablo Andres Moncada, Anna Nikolaevna Galustyan, Dany Badibanga Musungaie, Julie M Strizki

NEJM Evid· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients.
Cameron M Douglas, Richard Barnard, Daniel Holder, Randi Leavitt, Diane Levitan, Julie Strizki

J Infect Dis· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Mixed-Methods Study Examining Adherence to and Acceptability of Intravaginal Rings for HIV Prevention: Behavioral Results of MTN-027.
José A Bauermeister, Jesse M Golinkoff, Alex Carballo-Diéguez, Rebecca Giguere, Daniela López, Julie Strizki

AIDS Behav· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal Rings.
Craig J Hoesley, Beatrice A Chen, Peter L Anderson, Charlene S Dezzutti, Julie Strizki

Clin Infect Dis· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Pharmacokinetic Trial of 2 Intravaginal Rings Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048.
Albert Y Liu, Jingyang Zhang, Peter L Anderson, Theresa Wagner, Zhenyu Pan, Julie Strizki

Clin Infect Dis· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.
Guoxin Wu, Michael Swanson, Aarthi Talla, Donald Graham, Julie Strizki

JCI Insight· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.
Maribel Rodriguez-Torres, Albrecht Stoehr, Edward J Gane, Lawrence Serfaty, Eric Lawitz, Julie Strizki

Clin Gastroenterol Hepatol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis.
Richard J O Barnard, Carolyn M McHale, William Newhard, Carol A Cheney, Donald J Graham, Julie Strizki

Virology· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies.
Richard J O Barnard, John A Howe, Robert A Ogert, Stefan Zeuzem, Fred Poordad, Julie Strizki

Virology· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis